Syndecan-1 (CD138) expression in human non-Hodgkin's lymphomas

被引：5
|
作者：
Sutcliffe, M
Oscier, D
Wright, DH
机构：
[1] Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England
[2] Royal Bournemouth Hosp, Dept Histopathol, Bournemouth BH7 7DW, Dorset, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2000年 / 110卷 / 01期
关键词：
syndecan-1(CD138); non-Hodgkin's lymphoma;
D O I：
10.1046/j.1365-2141.2000.02072-5.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：239 / 240
页数：2
相关论文
共 50 条
  • [21] A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer
    Kind, Simon
    Jaretzke, Annika
    Buescheck, Franziska
    Moeller, Katharina
    Dum, David
    Hoeflmayer, Doris
    Hinsch, Andrea
    Weidemann, Soren
    Fraune, Christoph
    Moeller-Koop, Christina
    Hube-Magg, Claudia
    Simon, Ronald
    Wilczak, Waldemar
    Lebok, Patrick
    Witzel, Isabell
    Mueller, Volkmar
    Schmalfeldt, Barbara
    Paluchowski, Peter
    Wilke, Christian
    Heilenkoetter, Uwe
    von Leffern, Ingo
    Krech, Till
    Krech, Rainer H.
    von der Assen, Albert
    Bawahab, Ahmed Abdulwahab
    Burandt, Eike
    MOLECULAR CARCINOGENESIS, 2019, 58 (12) : 2306 - 2315
  • [22] Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas
    Bologna-Molina, R.
    Mosqueda-Taylor, A.
    Lopez-Corella, E.
    Almeida, O. P.
    Carrasco-Daza, D.
    Garcia-Vazquez, F.
    Farfan-Morales, J. E.
    Irigoyen-Camacho, M. E.
    Damian-Matsumura, P.
    ORAL ONCOLOGY, 2008, 44 (08) : 805 - 811
  • [23] Utility of CD138 (Syndecan-1) in distinguishing carcinomas from mesotheliomas
    Yun, SS
    Borczuk, AC
    Powell, CA
    Yu, GH
    Alexis, D
    Saqi, A
    LABORATORY INVESTIGATION, 2005, 85 : 81A - 81A
  • [24] Utility of CD138 (Syndecan-1) in distinguishing carcinomas from mesotheliomas
    Saqi, A
    Yun, SS
    Yu, GH
    Alexis, D
    Taub, RN
    Powell, CA
    Borczuk, AC
    DIAGNOSTIC CYTOPATHOLOGY, 2005, 33 (02) : 65 - 70
  • [25] Utility of CD138 (Syndecan-1) in distinguishing carcinomas from mesotheliomas
    Yun, SS
    Borczuk, AC
    Powell, CA
    Yu, GH
    Alexis, D
    Saqi, A
    MODERN PATHOLOGY, 2005, 18 : 81A - 81A
  • [26] Syndecan-1 (CD138) expression in normal tissues and non-hematolymphoid neoplasms using tissue microarrays
    Kambham, N
    Longacre, T
    Natkunam, Y
    MODERN PATHOLOGY, 2003, 16 (01) : 238A - 238A
  • [27] Syndecan-1 (CD138) expression in normal tissues and non-hematolymphoid neoplasms using tissue microarrays
    Kambham, N
    Longacre, T
    Natkunam, Y
    LABORATORY INVESTIGATION, 2003, 83 (01) : 238A - 238A
  • [28] Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade
    Gokden, Neriman
    Greene, Graham F.
    Bayer-Garner, Ilene B.
    Spencer, Horace J.
    Sanderson, Ralph D.
    Gokden, Murat
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2006, 14 (02) : 173 - 177
  • [29] Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis
    Chen, Chi-Long
    Ou, Da-Liang
    HUMAN PATHOLOGY, 2006, 37 (10) : 1279 - 1285
  • [30] Syndecan-1 (CD138) expression is related to an aggressive phenotype and to poorer prognosis to breast carcinoma
    Barbareschi, M
    Aldovini, D
    Maisonneuve, P
    Cangi, MG
    Pecciarini, L
    Mauri, FA
    Caffo, O
    Galligioni, E
    Dalla Palma, P
    Doglioni, C
    LABORATORY INVESTIGATION, 2001, 81 (01) : 21A - 21A
12345